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Background
A variety of autologous tumor/dendritic-cell (DC) vac-
cines have been pursued. Our prior autologous tumor/
DC fusion (dendritoma) vaccine demonstrated clinical
benefit in metastatic melanoma; however, dendritoma
production is difficult and not scalable for commerciali-
zation. We developed an alternative, novel approach to
efficiently deliver the autologous tumor antigenic reper-
toire to the cytoplasm of phagocytic-DC using yeast cell
wall particles (YCWP). We describe the in vitro and ani-
mal data supporting clinical development of our tumor
lysate, particle-loaded, DC(TLPLDC) vaccine.
Methods
YCWP are prepared, leaving beta glycan hollow spheres
with large pores capable of loading. TL is produced
from multiple freeze/thaw cycles and loaded in YCWP.
Monocyte-derived DC are isolated and matured. Using
the ovalbumin/B3Z cell system, spectrophotometric ana-
lysis confirmed antigen presentation via YCWP vs exo-
genous loading. In vivo effectiveness of TLPLDC
compared to dendritomas and controls was assessed in
a murine melanoma pulmonary metastasis model
(MMPMM). DC were prepared from mouse bone mar-
row, and YCWP loaded with TL from the B16F0 murine
melanoma cells. Treatment group mice were inoculated
intradermally with 1×106 TLPLDC one week prior to
tumor challenge and repeated for three weekly doses.
Controls were inoculated similarly with saline, irradiated
tumor cells, empty DC, fusion mixtures or dendritomas.
All mice were injected intravenously with 5×105 B16
tumor cells. Upon death of the first animal, all were
sacrificed, lungs harvested, and pulmonary metastases
totaled. In another comparison, untreated control ani-
mals were compared to TLPLDC-treated with and with-
out CpG adjuvant for survival. Statistical analyses were
performed using t-test or ANOVA as indicated.
Results
Based on spectrophotometric analysis, the ovalbumin
loaded YCWP-fed DC produced a 100-fold increase in
epitope-specific CD8+ T cell responses compared to tra-
ditional exogenously loaded DC. In the MMPMM,
TLPLDC inoculations resulted in zero metastases com-
pared to saline (198+1.5 mets), irradiated tumor cells
(>200), empty DC (>200), fusion mixture (112+25), and
dendritoma (3.13+1.5) controls(n=8, each; all p < 0.01).
Median survival of untreated controls was 21 days,
TLPLDC inoculated was 29 days and TLPLDC+CpG
inoculated was 41 days (n=10, each).
Conclusions
YCWP are more effective than exogenous antigen loading
of DC and produce a robust CD8+ T cell response. In
the virulent B16 murine melanoma model, TLPLDC, and
particularly TLPLDC+CpG, produced long-term survival
and out-performed our previous dendritoma vaccine
which demonstrated clinical benefit in Phase I/IIa trials
in metastatic melanoma patients. This data bridges our
previous tumor/DC fusion technology to the novel
TLPLDC and supports clinical development of the
TLPLDC vaccine.
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